Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Aslan Pharma Repurposes DHODH Inhibitor for Autoimmune, COVID-19 Indications

publication date: Oct 16, 2020

Singapore's Aslan Pharma announced plans to develop ASLAN003, its next-gen dihydroorotate dehydrogenase (DHODH) inhibitor in autoimmune conditions, such as multiple sclerosis (MS). It will also test the candidate as a treatment for COVID-19 and other viral infections. According to Aslan, ASLAN003 has shown 30 times the potency for inhibiting the DHODH enzyme in pre-clinical tests as first-gen molecules. In 2019, Aslan completed a Phase II trial of ASLAN003 in AML, but decided not to continue its development for the indication. More details....

Stock Symbols: (NSDQ: ASLN)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital